Hologic hands former Stryker CEO Steven MacMillan the keys to the corner office, agrees to take on 2 new board members to pacify an activist investor and enlists a new scientific advisor.
Massachusetts medtech maker Hologic (NSDQ:HOLX) did some top-line rearranging, naming Steven MacMillan its new CEO and adding 2 members to its board of directors to appease an activist investor.
New CEO MacMillan has spent some 24 years in the medtech space, perhaps most notably as president & CEO for Stryker (NYSE:SYK). MacMillan resigned from Stryker’s top spot in February 2012 amid a flurry of rumors and speculation about his personal life.
